Simon, Gallagher, Glick, Shimsky, Reyes, Cruz, Levenberg, Walker, Taylor, Raga, De Los Santos
MLTSPNSR
Add §267-c, Pub Health L
Relates to the menstrual product safety and research act and its creation of a research program to determine the risks posed from potential toxins in menstrual products.
STATE OF NEW YORK
________________________________________________________________________
1303
2025-2026 Regular Sessions
IN ASSEMBLY
January 9, 2025
___________
Introduced by M. of A. ROSENTHAL, SIMON, GALLAGHER, GLICK, SHIMSKY,
REYES, CRUZ, LEVENBERG, WALKER, TAYLOR, RAGA, DE LOS SANTOS -- read
once and referred to the Committee on Health
AN ACT to amend the public health law, in relation to the creation of a
research program to determine the risks posed from potential toxins in
menstrual products; and providing for the repeal of such provisions
upon expiration thereof
The People of the State of New York, represented in Senate and Assem-bly, do enact as follows:
1 Section 1. Short title. This act shall be known and may be cited as
2 "the menstrual product safety and research act".
3 § 2. The public health law is amended by adding a new section 267-c to
4 read as follows:
5 § 267-c. Menstrual product safety and research. 1. For purposes of
6 this section, the term "menstrual products" means tampons, pads, liners,
7 cups, sponges, douches, wipes, sprays, and similar products used in
8 conjunction with respect to menstruation or other genital-tract
9 secretions.
10 2. The commissioner shall provide for the conduct or support of
11 research by the department to determine the extent to which the presence
12 of dioxins, synthetic fibers, chlorine, and other components (including
13 contaminants and substances used as fragrances, colorants, dyes, and
14 preservatives) in menstrual products:
15 (a) poses any risks to the health of individuals who use the products,
16 including risks relating to cervical cancer, endometriosis, infertility,
17 ovarian cancer, breast cancer, immune system deficiencies, pelvic
18 inflammatory disease, toxic shock syndrome, and bacterial and yeast
19 infections; and
20 (b) poses any risks to the health of biological children born to indi-
21 viduals who used such products during or before the pregnancies
22 involved, including risks relating to fetal and childhood development.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[] is old law to be omitted.
LBD03818-01-5
A. 1303 2
1 3. Research under subdivision two of this section shall include
2 research to confirm the data on menstrual products submitted to the
3 United States food and drug administration by manufacturers of such
4 products.
5 4. Such research projects shall be completed within four years of the
6 effective date of this section.
7 5. Within one year of the completion of such research, any conclu-
8 sions, recommendations and proposals for implementing such recommenda-
9 tions shall be transmitted to the governor, the temporary president of
10 the senate, the speaker of the assembly, the chair of the senate health
11 committee, and the chair of the assembly health committee, and shall
12 also be made available to the public.
13 § 3. This act shall take effect on the ninetieth day after it shall
14 have become a law and shall expire and be deemed repealed five years
15 after such date.
